FDA approves new HIV drug after priority review.
D000284:Administration, Oral; D000328:Adult; D004311:Double-Blind Method; D017277:Drug Approval / Q000331:legislation & jurisprudence*; D005260:Female; D015658:HIV Infections / Q000188:drug therapy; D006801:Humans; D008297:Male; D009570:Nitriles; D011724:Pyridazines / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D011743:Pyrimidines; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome; D014481:United States; D014486:United States Food and Drug Administration
D009570:Nitriles; D011724:Pyridazines; D011743:Pyrimidines; C451734:etravirine